{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:35:34Z","timestamp":1776990934504,"version":"3.51.4"},"reference-count":81,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T00:00:00Z","timestamp":1626825600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003852","name":"Regione Campania","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003852","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.isci.2021.102898","type":"journal-article","created":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T19:36:54Z","timestamp":1626982614000},"page":"102898","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Effect of time and titer in convalescent plasma therapy for COVID-19"],"prefix":"10.1016","volume":"24","author":[{"given":"Paola","family":"de Candia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2959-2658","authenticated-orcid":false,"given":"Francesco","family":"Prattichizzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Garavelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2224-4615","authenticated-orcid":false,"given":"Rosalba","family":"La Grotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annunziata","family":"De Rosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agostina","family":"Pontarelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Parrella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Ceriello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9429-0616","authenticated-orcid":false,"given":"Giuseppe","family":"Matarese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2021.102898_bib1","doi-asserted-by":"crossref","first-page":"102875","DOI":"10.1016\/j.transci.2020.102875","article-title":"Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: results of a multicenter clinical study","volume":"59","author":"Abolghasemi","year":"2020","journal-title":"Transfus. Apher. Sci."},{"key":"10.1016\/j.isci.2021.102898_bib2","doi-asserted-by":"crossref","first-page":"m3939","DOI":"10.1136\/bmj.m3939","article-title":"Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)","volume":"371","author":"Agarwal","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.isci.2021.102898_bib3","article-title":"Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease","author":"AlQahtani","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.isci.2021.102898_bib4","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ijid.2020.11.198","article-title":"COVID-19 convalescent plasma treatment of moderate and severe cases of SARS-CoV-2 infection: a multicenter interventional study","volume":"103","author":"Alsharidah","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.isci.2021.102898_bib5","doi-asserted-by":"crossref","first-page":"103017","DOI":"10.1016\/j.transci.2020.103017","article-title":"Convalescent plasma therapy in patients with COVID-19","volume":"60","author":"Altuntas","year":"2021","journal-title":"Transfus. Apher. Sci."},{"key":"10.1016\/j.isci.2021.102898_bib6","first-page":"15","article-title":"Prognostic value of antithrombin levels in COVID-19 patients and impact of fresh frozen plasma treatment: a retrospective study","volume":"38","author":"Anakli","year":"2021","journal-title":"Turk J. Haematol."},{"key":"10.1016\/j.isci.2021.102898_bib7","article-title":"Convalescent Plasma for COVID-19: a multicenter, randomized clinical trial","author":"Avendano-Sola","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.isci.2021.102898_bib8","doi-asserted-by":"crossref","first-page":"e1003415","DOI":"10.1371\/journal.pmed.1003415","article-title":"Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: a randomized phase II clinical trial","volume":"18","author":"Balcells","year":"2021","journal-title":"PLoS Med."},{"key":"10.1016\/j.isci.2021.102898_bib9","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1093\/infdis\/jiaa581","article-title":"SARS-CoV-2 antibody avidity responses in COVID-19 patients and convalescent plasma donors","volume":"222","author":"Benner","year":"2020","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.isci.2021.102898_bib10","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.cytogfr.2020.04.005","article-title":"Inflamm-aging: why older men are the most susceptible to SARS-CoV-2 complicated outcomes","volume":"53","author":"Bonafe","year":"2020","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.isci.2021.102898_bib11","doi-asserted-by":"crossref","first-page":"e144930","DOI":"10.1172\/JCI144930","article-title":"Clinical, laboratory, and temporal predictors of neutralizing antibodies against SARS-CoV-2 among COVID-19 convalescent plasma donor candidates","volume":"131","author":"Boonyaratanakornkit","year":"2021","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.isci.2021.102898_bib12","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/s41423-020-00573-9","article-title":"Low serum neutralizing anti-SARS-CoV-2\u00a0S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods","volume":"18","author":"Bosnjak","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.isci.2021.102898_bib13","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1093\/infdis\/jiaa505","article-title":"Severe acute respiratory syndrome coronavirus 2 neutralizing antibody titers in convalescent plasma and recipients in New Mexico: an open treatment study in patients with coronavirus disease 2019","volume":"222","author":"Bradfute","year":"2020","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.isci.2021.102898_bib14","doi-asserted-by":"crossref","first-page":"102548","DOI":"10.1016\/j.bcmd.2021.102548","article-title":"Effectiveness of convalescent plasma in Indian patients with COVID-19","volume":"88","author":"Budhiraja","year":"2021","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.isci.2021.102898_bib15","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s41586-021-03471-w","article-title":"Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma","volume":"593","author":"Cele","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.isci.2021.102898_bib16","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/S2666-5247(20)30172-5","article-title":"SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis","volume":"2","author":"Cevik","year":"2021","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.isci.2021.102898_bib17","first-page":"CD013600","article-title":"Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review","volume":"7","author":"Chai","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.isci.2021.102898_bib18","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S1473-3099(20)30141-9","article-title":"Convalescent plasma as a potential therapy for COVID-19","volume":"20","author":"Chen","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.isci.2021.102898_bib19","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s10096-004-1271-9","article-title":"Use of convalescent plasma therapy in SARS patients in Hong Kong","volume":"24","author":"Cheng","year":"2005","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.isci.2021.102898_bib20","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1056\/NEJMe2034495","article-title":"Monoclonal antibodies to disrupt progression of early covid-19 infection","volume":"384","author":"Cohen","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.isci.2021.102898_bib21","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s40121-020-00318-1","article-title":"That escalated quickly: remdesivir's place in therapy for COVID-19","volume":"9","author":"Davis","year":"2020","journal-title":"Infect. Dis. Ther."},{"key":"10.1016\/j.isci.2021.102898_bib22","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/trf.16202","article-title":"Blood component utilization in COVID-19 patients in New York City: transfusions do not follow the curve","volume":"61","author":"DeSimone","year":"2021","journal-title":"Transfusion"},{"key":"10.1016\/j.isci.2021.102898_bib23","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s42003-021-01649-6","article-title":"SARS-CoV-2 specific antibody and neutralization assays reveal the wide range of the humoral immune response to virus","volume":"4","author":"Dogan","year":"2021","journal-title":"Commun. Biol."},{"key":"10.1016\/j.isci.2021.102898_bib24","doi-asserted-by":"crossref","first-page":"e143196","DOI":"10.1172\/jci.insight.143196","article-title":"Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma","volume":"6","author":"Donato","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.isci.2021.102898_bib25","doi-asserted-by":"crossref","first-page":"9490","DOI":"10.1073\/pnas.2004168117","article-title":"Effectiveness of convalescent plasma therapy in severe COVID-19 patients","volume":"117","author":"Duan","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.isci.2021.102898_bib26","doi-asserted-by":"crossref","first-page":"102922","DOI":"10.1016\/j.transci.2020.102922","article-title":"SARS-CoV-2 serology and virology trends in donors and recipients of convalescent plasma","volume":"59","author":"Dulipsingh","year":"2020","journal-title":"Transfus. Apher. Sci."},{"key":"10.1016\/j.isci.2021.102898_bib27","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.jcrc.2020.07.001","article-title":"Therapeutic plasma exchange in adult critically ill patients with life-threatening SARS-CoV-2 disease: a pilot study","volume":"60","author":"Faqihi","year":"2020","journal-title":"J.\u00a0Crit. Care"},{"key":"10.1016\/j.isci.2021.102898_bib28","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00072-20","article-title":"Convalescent plasma therapy for COVID-19: state of the art","volume":"33","author":"Focosi","year":"2020","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.isci.2021.102898_bib29","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/ejh.13630","article-title":"Clinical predictors of SARS-CoV-2 neutralizing antibody titers in COVID-19 convalescents: implications for convalescent plasma donor recruitment","volume":"107","author":"Focosi","year":"2021","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.isci.2021.102898_bib30","article-title":"Convalescent Plasma for COVID-19. A randomized clinical trial","author":"Gharbharan","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.isci.2021.102898_bib31","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/s42003-021-01813-y","article-title":"Limited window for donation of convalescent plasma with high live-virus neutralizing antibody titers for COVID-19 immunotherapy","volume":"4","author":"Gontu","year":"2021","journal-title":"Commun. Biol."},{"key":"10.1016\/j.isci.2021.102898_bib32","first-page":"417","article-title":"[Convalescent plasma therapy in COVID-19 patients, in the province of buenos aires]","volume":"80","author":"Gonz\u00e1lez","year":"2020","journal-title":"Medicina (B Aires)"},{"key":"10.1016\/j.isci.2021.102898_bib34","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1182\/blood.2020006964","article-title":"Use of convalescent plasma in hospitalized patients with COVID-19: case series","volume":"136","author":"Hegerova","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.isci.2021.102898_bib35","article-title":"Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","author":"Horby","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/j.isci.2021.102898_bib36","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.isci.2021.102898_bib37","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.ijid.2020.10.085","article-title":"Therapeutic plasma exchange followed by convalescent plasma transfusion in critical COVID-19-An exploratory study","volume":"102","author":"Jaiswal","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.isci.2021.102898_bib38","article-title":"Donor anti-spike immunity is related to recipient recovery and can predict the efficacy of convalescent plasma units","author":"Janaka","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/j.isci.2021.102898_bib39","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa2031893","article-title":"Convalescent plasma antibody levels and the risk of death from covid-19","volume":"384","author":"Joyner","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.isci.2021.102898_bib40","doi-asserted-by":"crossref","first-page":"e0244853","DOI":"10.1371\/journal.pone.0244853","article-title":"Therapeutic plasma exchange for coronavirus disease-2019 triggered cytokine release syndrome; a retrospective propensity matched control study","volume":"16","author":"Kamran","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.isci.2021.102898_bib41","article-title":"Evidence favoring the efficacy of convalescent plasma for COVID-19 therapy","author":"Klassen","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.isci.2021.102898_bib42","doi-asserted-by":"crossref","first-page":"6141","DOI":"10.1172\/JCI142004","article-title":"Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population","volume":"130","author":"Klein","year":"2020","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.isci.2021.102898_bib43","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1001\/jama.2020.10044","article-title":"Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial","volume":"324","author":"Li","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.isci.2021.102898_bib44","doi-asserted-by":"crossref","first-page":"e138070","DOI":"10.1172\/jci.insight.138070","article-title":"Clinical and pathological investigation of severe COVID-19 patients","volume":"5","author":"Li","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.isci.2021.102898_bib45","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa2033700","article-title":"Early high-titer plasma therapy to prevent severe covid-19 in older adults","volume":"384","author":"Libster","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.isci.2021.102898_bib46","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1038\/s41591-020-1088-9","article-title":"Convalescent plasma treatment of severe COVID-19: a propensity score\u2013matched control study","volume":"26","author":"Liu","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2021.102898_bib47","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding","volume":"395","author":"Lu","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.isci.2021.102898_bib48","article-title":"Clinical predictors of donor antibody titer and correlation with recipient antibody response in a COVID-19 convalescent plasma clinical trial","author":"Madariaga","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.isci.2021.102898_bib49","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/infdis\/jiu396","article-title":"The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis","volume":"211","author":"Mair-Jenkins","year":"2015","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.isci.2021.102898_bib50","doi-asserted-by":"crossref","first-page":"102847","DOI":"10.1016\/j.transci.2020.102847","article-title":"The true historical origin of convalescent plasma therapy","volume":"59","author":"Marson","year":"2020","journal-title":"Transfus. Apher. Sci."},{"key":"10.1016\/j.isci.2021.102898_bib51","doi-asserted-by":"crossref","first-page":"2001754","DOI":"10.2807\/1560-7917.ES.2020.25.45.2001754","article-title":"Convalescent plasma for COVID-19: male gender, older age and hospitalisation associated with high neutralising antibody levels, England, 22 April to 12 May 2020","volume":"25","author":"Mehew","year":"2020","journal-title":"Euro Surveill."},{"key":"10.1016\/j.isci.2021.102898_bib52","doi-asserted-by":"crossref","first-page":"e146927","DOI":"10.1172\/JCI146927","article-title":"Antibody responses to endemic coronaviruses modulate COVID-19 convalescent plasma functionality","volume":"131","author":"Morgenlander","year":"2021","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.isci.2021.102898_bib53","first-page":"159","article-title":"Infusion of convalescent plasma is associated with clinical improvement in critically ill patients with covid-19: a pilot study","volume":"72","author":"Olivares-Gazca","year":"2020","journal-title":"Rev. Invest. Clin."},{"key":"10.1016\/j.isci.2021.102898_bib54","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1002\/jmv.26537","article-title":"Convalescent plasma for the treatment of patients with severe coronavirus disease 2019: a preliminary report","volume":"93","author":"Omrani","year":"2021","journal-title":"J.\u00a0Med. Virol."},{"key":"10.1016\/j.isci.2021.102898_bib55","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.3324\/haematol.2020.261784","article-title":"Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter trial","volume":"105","author":"Perotti","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.isci.2021.102898_bib56","first-page":"1","article-title":"A randomized clinical trial evaluating the immunomodulatory effect of convalescent plasma on COVID-19-related cytokine storm","author":"Pouladzadeh","year":"2021","journal-title":"Intern. Emerg. Med."},{"key":"10.1016\/j.isci.2021.102898_bib57","first-page":"357","article-title":"The therapeutic potential of convalescent plasma therapy on treating critically-ill COVID-19 patients residing in respiratory care units in hospitals in Baghdad, Iraq","volume":"28","author":"Rasheed","year":"2020","journal-title":"Infez Med."},{"key":"10.1016\/j.isci.2021.102898_bib33","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with covid-19 - preliminary report","volume":"384","author":"RECOVERY Collaborative Group","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.isci.2021.102898_bib58","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1016\/j.ajpath.2020.08.001","article-title":"Treatment of coronavirus disease 2019 patients with convalescent plasma reveals a signal of significantly decreased mortality","volume":"190","author":"Salazar","year":"2020","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.isci.2021.102898_bib59","doi-asserted-by":"crossref","first-page":"6728","DOI":"10.1172\/JCI141206","article-title":"Convalescent plasma anti-SARS-CoV-2 spike protein ectodomain and receptor-binding domain IgG correlate with virus neutralization","volume":"130","author":"Salazar","year":"2020","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.isci.2021.102898_bib60","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/jmv.26408","article-title":"Convalescent plasma is a clutch at straws in COVID-19 management! A systematic review and meta-analysis","volume":"93","author":"Sarkar","year":"2021","journal-title":"J.\u00a0Med. Virol."},{"key":"10.1016\/j.isci.2021.102898_bib61","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/bjh.17272","article-title":"Early mortality benefit with COVID-19 convalescent plasma: a matched control study","volume":"192","author":"Shenoy","year":"2021","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.isci.2021.102898_bib62","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1056\/NEJMoa2031304","article-title":"A randomized trial of convalescent plasma in covid-19 severe pneumonia","volume":"384","author":"Simonovich","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.isci.2021.102898_bib63","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ijid.2020.09.1432","article-title":"Clinical management and mortality among COVID-19 cases in sub-Saharan Africa: a retrospective study from Burkina Faso and simulated case analysis","volume":"101","author":"Skrip","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.isci.2021.102898_bib64","doi-asserted-by":"crossref","first-page":"173644","DOI":"10.1016\/j.ejphar.2020.173644","article-title":"Treatment for COVID-19: an overview","volume":"889","author":"Stasi","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.isci.2021.102898_bib65","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1016\/j.cell.2021.02.033","article-title":"Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera","volume":"184","author":"Supasa","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.isci.2021.102898_bib66","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.3390\/microorganisms8121885","article-title":"Anti-SARS-CoV-2 antibody responses in convalescent plasma donors are increased in hospitalized patients; subanalyses of a phase 2 clinical study","volume":"8","author":"Terpos","year":"2020","journal-title":"Microorganisms"},{"key":"10.1016\/j.isci.2021.102898_bib67","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2021.1799","article-title":"Association of convalescent plasma therapy with survival in patients with hematologic cancers and COVID-19","author":"Thompson","year":"2021","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.isci.2021.102898_bib68","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1182\/blood.2020007638","article-title":"Earlier the better: convalescent plasma","volume":"136","author":"Tobian","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.isci.2021.102898_bib69","doi-asserted-by":"crossref","first-page":"8571","DOI":"10.1002\/cam4.3457","article-title":"Convalescent plasma for the treatment of severe COVID-19 infection in cancer patients","volume":"9","author":"Tremblay","year":"2020","journal-title":"Cancer Med."},{"issue":"Suppl 6","key":"10.1016\/j.isci.2021.102898_bib70","first-page":"9","article-title":"[Convalescent plasma as a therapy for severe COVID-19 pneumonia]","volume":"80","author":"Valentini","year":"2020","journal-title":"Medicina (B Aires)"},{"key":"10.1016\/j.isci.2021.102898_bib71","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1111\/trf.16401","article-title":"Exponential increase in neutralizing and spike specific antibodies following vaccination of COVID-19 convalescent plasma donors","volume":"61","author":"Vickers","year":"2021","journal-title":"Transfusion"},{"key":"10.1016\/j.isci.2021.102898_bib72","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.chom.2021.04.007","article-title":"Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization","volume":"29","author":"Wang","year":"2021","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.isci.2021.102898_bib73","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41586-021-03398-2","article-title":"Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7","volume":"593","author":"Wang","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.isci.2021.102898_bib74","doi-asserted-by":"crossref","first-page":"100763","DOI":"10.1016\/j.cegh.2021.100763","article-title":"The predictors of high titer of anti-SARS-CoV-2 antibody of convalescent plasma donors","volume":"11","author":"Wardhani","year":"2021","journal-title":"Clin. Epidemiol. Glob. Health"},{"key":"10.1016\/j.isci.2021.102898_bib75","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/s41591-021-01285-x","article-title":"SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma","volume":"27","author":"Wibmer","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2021.102898_bib76","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1182\/blood.2020007079","article-title":"Improved clinical symptoms and mortality among patients with severe or critical COVID-19 after convalescent plasma transfusion","volume":"136","author":"Xia","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.isci.2021.102898_bib77","first-page":"e142270","article-title":"Treatment of severe COVID-19 with convalescent plasma in Bronx, NYC","volume":"6","author":"Yoon","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.isci.2021.102898_bib78","doi-asserted-by":"crossref","first-page":"12528","DOI":"10.1073\/pnas.2006961117","article-title":"Convalescent plasma for patients with COVID-19","volume":"117","author":"Zeng","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.isci.2021.102898_bib79","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.isci.2021.102898_bib80","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.isci.2021.102898_bib81","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N.\u00a0Engl. J. Med."}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258900422100866X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258900422100866X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T16:33:14Z","timestamp":1762878794000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S258900422100866X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":81,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S258900422100866X"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2021.102898","relation":{},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of time and titer in convalescent plasma therapy for COVID-19","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2021.102898","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors.","name":"copyright","label":"Copyright"}],"article-number":"102898"}}